Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool May 6, 2008 Brian Lawler	MannKind Moves Ahead The pharmaceutical awaits pivotal data on its lead drug Technosphere.
The Motley Fool September 19, 2006 Brian Lawler	A Long Wait for MannKind The company's inhaled insulin might not reach the market for several years, if it does, but it's a big market. Investors, take note.
The Motley Fool April 14, 2008 Brian Lawler	MannKind Gets Smacked by Big Brother's Bad News Bad news for a competitor sinks MannKind shares.
The Motley Fool March 16, 2010 Brian Orelli	How to Lose $114 Million in One Day You've got to be a very trusting investor to buy shares in pharmaceutical company, MannKind.
The Motley Fool January 16, 2008 Brian Lawler	Another Inhalable Insulin Bites the Dust Novo Nordisk discontinues development of its troubled diabetes treatment and settles its patent infringement lawsuit against Pfizer. Investors, take note.
The Motley Fool June 29, 2011 Brian Orelli	So Much Insulin, So Little Use for It MannKind settles its supply agreement with Merck.
The Motley Fool June 11, 2010 Brian Orelli	Double-Digit Pop Because the Drug Still Works? Developments at Mannkind's shareholder meeting send stock soaring.
The Motley Fool December 28, 2010 Brian Orelli	Double-Digit Increase! Haven't We Learned Anything? MannKind's investors need a history lesson.
The Motley Fool July 30, 2010 Brian Orelli	MannKind: Strengths, Weaknesses, Opportunities, Threats It's all about the inhaled insulin.
The Motley Fool December 27, 2011 Brian Orelli	2011 No Dreamboat for MannKind An FDA rejection and a long wait is a bad combination.
The Motley Fool December 5, 2008 Brian Orelli	Be Kind to MannKind MannKind has good data on its inhaled insulin drug, but will the FDA approve of it and will diabetics buy it?
The Motley Fool June 27, 2011 Brian Orelli	Data Galore, but Where's the FDA Approval? Presentations at the American Diabetes Association won't help with approvals.
The Motley Fool June 19, 2009 Robert Steyer	MannKind Needs More Leaps Getting FDA approval for its inhaled-insulin product is only one hurdle for this start-up pharmaceutical.
The Motley Fool August 12, 2011 Evan Niu	One Small Step for Afrezza, One Giant Leap for MannKind Afrezza makes headway toward FDA approval.
The Motley Fool September 22, 2010 Brian Orelli	Better Buy: Amylin Pharmaceuticals or MannKind? It's a diabetes-drug showdown.
The Motley Fool August 6, 2007 Brian Lawler	Unhappy Delays for MannKind Two delays for the inhalable insulin developer cause the stock to drop.
The Motley Fool January 20, 2011 Brian Orelli	This Stock Is No Dreamboat The FDA is not kind to MannKind.
The Motley Fool May 10, 2011 Brian Orelli	Waiting for MannKind's Pot of Gold It's going to be awhile.
Pharmaceutical Executive May 1, 2009	The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded?
The Motley Fool June 27, 2005 Stephen D. Simpson	Sniffing Out a Possible Diabetes Blockbuster Inhaled insulin has been a Holy Grail of diabetes care. Will it live up to lofty expectations? Pfizer, Sanofi-Aventis, and Lilly are all interesting in their own right as high-quality pharmaceutical companies, and more aggressive investors should take a look at Nektar and Alkermes, as well.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool January 31, 2011 Brian Orelli	5 Drugmakers Headed Back to the Drawing Board Sometimes an FDA rejection is more of a to-do list.
The Motley Fool February 11, 2011 Brian Orelli	Biotech Optimists Throw In the Towel As the chance of survival improves, the stock falls. Wait, what?
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool December 31, 2009 Brian Orelli	2010 FDA Decisions to Watch It's a pivotal year for these drugmakers.
The Motley Fool June 29, 2010 Brian Orelli	Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both.
Chemistry World August 12, 2014 Phillip Broadwith	Sanofi snaps up inhaled insulin license Sanofi has struck a licensing deal with US firm Mannkind to develop and commercialize Mannkind's recently-approved Afrezza inhaled insulin powder for global distribution.
The Motley Fool April 30, 2008 Brian Lawler	Alexza Advances 2 More Drugs The pharmaceutical company's compounds keep zipping through clinical trials.
Chemistry World June 30, 2014 Phillip Broadwith	Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently.
The Motley Fool August 18, 2011 Brian Orelli	Running the Correct Trial Isn't Enough MELA Sciences' stock is up on claim that their trial meets FDA guidance, but they still need to prove that the device actually works.
The Motley Fool July 27, 2010 Jim Mueller	3 Stocks to Play Biotech Here are three promising ideas for this exciting area.
The Motley Fool July 21, 2005 Stephen D. Simpson	Tiger Lilly or Wilting Daisy? For now, Lilly seems to me to be a middle-of-the-road type of pharmaceutical stock. There are plenty of worse ideas out there, but there are better ideas, as well.
The Motley Fool September 9, 2005 Stephen D. Simpson	Diabetics Breathing Easier Investors in Pfizer, Sanofi-Aventis, and Nektar Therapeutics might be breathing a bit easier today. The FDA's expert panel recommended approval for Exubera.
The Motley Fool April 11, 2007 Brian Lawler	Get Rich With These Guys Regardless of what type of long-term investment strategy you use, finding companies created under the auspices of proven entrepreneurs such as Moll, Zaffaroni, and Mann and then sticking with them for the long run is one path to investing riches.
Pharmaceutical Executive March 1, 2006 Ron Feemster	Holding Their Breath: Inhaled Insulin Exubera, Pfizer's inhaled-insulin therapy, is carving out a new market for diabetes drugs. Four more companies are looking for their share.
The Motley Fool August 10, 2010 Jeremy Phillips	Technically, MannKind Is a Buy For MannKind, it's all about Afrezza, an inhaled insulin that attempts to succeed where other drug companies have failed.
The Motley Fool May 22, 2006 Stephen D. Simpson	Nektar Full of Potential, Risk Can inhaled insulin sales live up to investors' expectations at Nektar Therapeutics?
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
The Motley Fool July 8, 2008 Brian Lawler	Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards.
The Motley Fool July 13, 2011 David Williamson	Roundtable: The Biggest Risks in Biotech Three biotech companies to steer clear of.
The Motley Fool March 2, 2005 Bill Mann	How Hated Is Pfizer? The FDA accepts Pfizer's application for what could be a monster drug, and the market yawns.
The Motley Fool January 13, 2006 Stephen D. Simpson	Pfizer Pays Sanofi to Go Away Two large pharmaceutical companies settle a dispute over inhaled insulin, and $1.3 billion changes hands. Investors, take note.
The Motley Fool November 24, 2010 Brian Orelli	Profit From the United States of Diabetes Half the country could have an early form by 2020.
The Motley Fool June 27, 2008 Brian Lawler	This Drug Market Is Booming One therapeutic category seems to be expanding significantly faster than most of its peers, the one that helps the unfortunately burgeoning number of diabetics in the U.S. and worldwide.
The Motley Fool September 30, 2011 Brian Orelli	A Drug Market That's 366 Million Strong Diabetes drugs have potential.
The Motley Fool February 4, 2008 Brian Lawler	Best International Stock: Novo Nordisk A quick summary of Danish drugmaker Novo Nordisk, the world's number one manufacturer of diabetes medications.
The Motley Fool November 25, 2011 Brian Orelli	7 Black Friday Biotech Bargains Get in at the right time to maximize your returns.
The Motley Fool February 8, 2011 Esterhuizen & Sellitti	Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch.
Pharmaceutical Executive November 1, 2013 Ben Comer	2014 Pipeline Report: The Sprint to Value Across a constellation of categories, bright new drugs are moving into position. The pharma model may have changed, but companies are keeping their blockbusters.